In vitro studies with mucoepidermoid cancer models positive for CRTC1-MAML2-positive present sensitivity to EGFR inhibitors, such as erlotinib, gefitinib, or cetuximab, that in the future can be an attractive therapeutic option. Here, MAML2 is linked to cancer.